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INTRODUCTION
Stomach cancer is the fourth most commonly diagnosed 
cancer with an average of 1 million patients newly diagnosed 
annually and was the second leading cause of cancer deaths 
worldwide in 2008 [1]. Prevalence and mortality are particularly 
high in East Asia, including South Korea [2]. The 5-year 
survival rate is more than 90% when cancer is detected as early 
gastric cancer (EGC), but it decreases to 30%–40% in cases of 
advanced gastric cancer (AGC) [3]. Thus, early detection and 
development of gastric cancer biomarkers are important for the 
treatment and survival of gastric cancer. Biomarkers such as 
carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-
9, and CA 72-4 have been investigated for years, but they are 
not recommended for screening and follow-up of gastric cancer 
in the National Comprehensive Cancer Network guidelines due 
Purpose: The aim of this study is to determine whether levels of circulating free DNA (cfDNA) increase according to cancer 
progression, whether they are restored after surgical resection, and to evaluate cfDNA in gastric cancer patients as a 
useful biomarker.
Methods: A case-control study design was used. Thirty gastric cancer patients and 34 healthy subjects were enrolled 
from two hospitals in South Korea. The plasma cfDNA of patients with gastric cancer were obtained before surgery and 24 
hours after surgery, and then analyzed by a quantitative, real-time polymerase chain reaction. Plasma samples were also 
obtained from the control group.
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was 96.67% and specificity was 94.11% when the cutoff value was 90 ng/mL. Variables representing the tumor burden 
such as tumor size, T stage, TNM stage, and curative resection are also associated with the levels of cfDNA. The levels of 
cfDNA in the 24-hour-after-surgery group decreased significantly (112.17 ± 13.42 ng/mL vs. 77.93 ± 5.94 ng/mL, P < 0.001) 
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to low sensitivity and specificity [4]. This limit of conventional 
biomarkers requires development of novel cancer biomarkers. 
As a cancer cell develops, circulating free DNA (cfDNA) 
is released into the blood stream with various physiologic 
events such as micrometastasis, necroptosis, apoptosis, and 
secretion [5]. CfDNA from the physiologic apoptosis of cells 
can be detected in healthy subjects [6] and is slightly prone 
to be increased in cases of trauma, sepsis, and other diseases 
such as systemic-lupus syndrome, pulmonary embolism, and 
myocardial infarction [7]. However, cfDNA in the plasma of 
cancer patients is 2–3 times higher than in normal healthy 
groups in various cancer studies [8]. Many studies suggest that 
circulating tumor cells or cfDNA can be alternative biomarkers 
for early detection of cancers, and predict prognosis and 
efficacy of therapies [8]. This cfDNA is also increased in benign 
preneoplastic tumors. Previous studies demonstrate that cfDNA 
is proportionally increased in benign colon polyps and colon 
cancers individually compared to normal groups [9]. Decreased 
cfDNA is mainly attributed to reduced tumor size by an 
operation and also rapid clearance by plasma nuclease such as 
DNAseI [10]. Previous studies demonstrated a half-life of cfDNA 
in plasma that ranges from minutes to hours. CfDNA can be 
a useful biomarker for the prediction of prognosis or cancer 
relapse. For example, one study demonstrated that the 2-year 
survival rate was 48% in cfDNA-detected groups and 100% in 
cfDNA-nondetected groups among colon cancer patients [11].
As many research outcomes point out cfDNA as a significant 
marker, cfDNA could be a good marker for early detection 
and follow-up treatment in gastric cancer. The purpose of this 
study was to determine the implication of cfDNA as a useful 
biomarker to detect EGC, to predict tumor burden and to detect 
residual tumor after surgery. 
METHODS
A cross-sectional case-and-control study design was applied to 
two Korean hospitals, located in a metropolitan area, between 
October 2012 and March 2013. 
Thirty gastric cancer patients who underwent a gastrectomy 
with a curative intent in Seoul Medical Center, and 34 age-
matched healthy controls who visited for regular health check-
ups in MizMedi Hospital, were recruited. A healthy control was 
defined as a subject who was not diagnosed of any cancerous 
condition in the past and currently does not have a serious 
illness, such as severe infection, sepsis, or trauma.
The case group is defined as patients who had been 
diagnosed with gastric cancer, which was pathologically 
confirmed by an endoscopic biopsy. Patients underwent either 
a laparoscopy or open surgery. Patients who underwent a 
palliative resection or who had prior chemotherapy, distant 
metastasis and double-primary cancer, were excluded. Data 
obtained for each patient included age, sex, body mass index 
(BMI), tumor marker (CEA, CA 19-9), tumor size, histologic 
type, T stage, N stage, gastric cancer stage classified according 
to the seventh edition of the American Joint Committee on 
Cancer staging criteria [12], and the preoperative and post-24-
hour operative serum cfDNA level. In the control group, healthy 
people who underwent an endoscopy for cancer screening were 
selected in order to obtain data. 
Many procedures, such as phenol-chloroform extraction, 
salting-out, magnetic beads, and triton/heat/phenol protocols 
[13] have been used to isolate cfDNA. To successfully isolate 
cfDNA from plasma, we empirically found that the efficacy 
of the extraction procedures is the key issue. We compared 
the efficacy of several commercial cfDNA-isolation kits based 
on column-based systems such as QIAamp DNA Micro kit 
(Qiagen, Valencia, CA, USA), Nucleospin Plasma XS (Macherey-
Nagel GmbH & Co. KG, Düren, Germany), and G-spin Total 
DNA Extraction kit (Intron biotechnology, Seongnam, Korea). 
Comparing plasma DNA yield and extent of DNA concentration 
variation from sample to sample, the QIAamp DNA Micro kit 
showed least variety in the amount of cell-free DNA among 
the 3 kits (data not shown). We reached the conclusion that 
the QIAamp DNA Micro kit provided robust and reliable 
cfDNA isolation. We routinely used 1.5-mL plasma as starting 
material, and the DNA was extracted according to the protocols 
instructed by the supplier. All blood samples were centrifuged 
once for 10 minutes at 4,000×g. From the withdrawn plasma, 
200 μL of plasma were dispensed to 7 microcentrifuge tubes 
per sample. Twenty-μL proteinase K and 4 μL of an RNase A 
stock solution were added to each tube. Then, 200 μL of Buffer 
AL was added to the sample and mixed thoroughly to yield a 
homogeneous solution. The tube was incubated at 56oC for 10 
minutes. Absolute ethanol (200 μL) was added to each reaction 
tube and then mixed by pulse-vortexing. For each sample, a 7 
microcentrifuge mixture was then applied to the same QIAamp 
mini spin column to increase the recovery yield and centrifuged 
at 9,000 rpm for 1 minute. Then the filtrate was discarded. 
Afterwards, 500 μL of Buffer AW1 was carefully added to the 
spin column and centrifuged at 9,000 rpm for 1 minute. Here 
again, the filtrate was discarded. Then 500 μL Buffer AW2 was 
added to the spin column and centrifuged at 13,000 rpm for 1 
minute. The QIAamp mini spin column was applied to a new 
collection tube and centrifuged at 13,000 rpm for 1 minute 
again. Finally, the spin column was placed in a clean 1.5-mL 
microcentrifuge tube and 50-μL Buffer AE was added. After 
incubation at room temperature for 5 minutes, it was then 
centrifuged at 13,000 rpm for 1 minute to elute the DNA. 
Descriptive and comparative analyses were done. Fisher exact 
test, Wilcoxon rank sum test, and the Kruscal-Wallis test were 
used to compare demographics and clinical characteristics. Post 
hoc multiple comparisons were calculated using Tukey method. 
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A receiver-operating characteristic (ROC) curve was generated 
to assess the cfDNA level as a diagnostic biomarker. A cutoff 
point was chosen, and then sensitivity, false-positive rate, and 
95% confidence intervals were calculated. A linear-regression 
model was used to adjust the covariants (including age and sex) 
affecting cfDNA. All tests were analyzed by IBM SPSS ver. 20.0 
(IBM Co., Armonk, NY, USA). 
This study was conducted prospectively after receiving 
permission from the local Institutional Review Board (No. 2012-
056). All patients participated voluntarily with written informed 
consents. 
RESULTS
The mean age was 66.72 ± 13.16 years in 30 gastric cancer 
patients, and 63.79 ± 6.76 years in 34 age-matched healthy 
subjects (P = 0.256). Aging cfDNA increases in gastric cancer 
patients (P < 0.01), but age and cfDNA are not correlated in the 
healthy control group (P = 0.969). CfDNA in females was higher 
than males in gastric cancer patients (P = 0.01), but not in the 
healthy control group (P = 0.598). CfDNA in nonsmokers was 
higher than smokers (P = 0.033) in gastric cancer patients, but 
not in the healthy control group (P = 0.375). Drinking alcohol, 
BMI, and Helicobacter pylori infection are not associated with 
cfDNA both in gastric cancer patients and the healthy control 
group (Table 1). 
Table 1. Mean levels of cfDNA according to clinical charateristics in gastric cancer and healthy control group
Variable
Case (n = 30) Control (n = 34)
No. Mean±SD P-value No. Mean±SD P-value
Age (yr) <0.001 0.969
   <65 13 102.31 ± 12.59 22 78.90 ± 8.55
   ≥65 17 119.71 ± 8.28 12 78.78 ± 7.17
Sex 0.010 0.598
   Male 23 110.00 ± 14.13 15 79.71 ± 6.85
   Female 7 119.29 ± 7.88 19 78.13 ± 9.11
Smoking 0.033 0.375
   Current 13 105.15 ± 12.88 4 82.25 ± 6.55
   Ex-smoker 3 114.33 ± 19.34 4 81.27 ± 3.45
   None 14 118.21 ± 10.09 26 78.35 ± 8.23
Alcohola) 0.141 0.263
   Severe 8 105.12 ± 13.55 2 84.22 ± 18.71
   Mild to moderate 2 108.50 ± 14.84 7 75.30 ± 12.84
   None 13 117.00 ± 12.55 15 76.06 ± 11.45
Body mass index (kg/m2) 0.334 0.189
   <23 19 114.00 ± 12.86 20 75.9 ± 7.4
   ≥23 11 109.00 ± 14.41 14 80.14 ± 8.12
H. pylori infection 0.209 0.348
   None 10 116.30 ± 9.742 20 80.35 ± 6.12
   Yes 8 107.88 ± 17.25 4 73.75 ± 11.78
   Not available 12 10
cfDNA, circulating free DNA; SD, standard deviation; H. pylori, Helicobacter pylori.
a)Total number of cases with alcohol history checked were 23 cases in gastric cancer patients group and 24 cases in healthy control 
group.
Fig. 1. Comparison of circulating free DNA among healthy 
subjects (white), early gastric cancer (EGC) groups (gray), and 
advanced gastric cancer (AGC, black) groups.
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Comparison of cfDNA between healthy individuals 
and gastric cancer patients
CfDNA was proportionally increased between healthy 
subjects, EGC patients, and AGC patients (79.78 ± 8.12 ng/
mL, 106.88 ± 12.40 ng/mL, and 120.23 ± 10.08 ng/mL, P < 
0.001) (Fig. 1, Table 2). Fig. 2 shows the ROC curves of cfDNA 
between the cancer patients and healthy controls. The area 
under the curve is 0.991. As the cutoff value of cfDNA is defined 
to 90 ng/mL, sensitivity, specificity, positive-prediction value, 
and negative-prediction value are 96.67%, 94.11%, 93.54%, and 
96.96%, respectively. 
Table 2 shows clinical data that represent tumor burden. 
cfDNA is higher in the AGC group than the EGC group, and this 
is significant after adjustment by age, sex, and smoking (P = 
0.004 and P = 0.035, respectively). CfDNA in the group with 
tumor sizes 5–9.9 cm is higher than in the group with tumor 
sizes <4.9 cm (P = 0.280, Tukey multiple-comparison test). 
Differentiation is not associated with cfDNA. The association 
between cfDNA and T stage is less significant (P = 0.065) but 
becomes significant after adjustment by age, sex and smoking (P 
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Table 2. Correlation between cfDNA and clinico-pathological data, which represents the invasiveness of gastric cancer
Variable No. Mean ± SD P-value unadjusted P-value adjusteda)
Cancer progression 0.004 0.035
   Early gastric cancer 16 106.88 ± 12.40
   Advanced gastric cancer 14 120.23 ± 10.08
Tumor size (cm) 0.005 0.045
   ≤4.9 18 107.17 ± 12.89
   5–9.9 9 120.89 ± 6.69
   ≥10 3 128.00 ± 0.00
Differentiation 0.701 0.779
   Differentiated 18 112.11 ± 14.02
   Undifferentiated 12 114.09 ± 11.99
T stage 0.065 0.037
   T1 16 108.06 ± 13.20
   T2, 3 6 110.83 ± 0.96
   T4 8 121.38 ± 13.42
N stage 0.344 0.096
   N0 22 110.00 ± 13.23
   N1, 2 3 121.50 ± 6.36
   N3 5 119.00 ± 15.58
TNM stage 0.076 0.048
   I 20 108.50 ± 12.93
   II, III 5 118.50 ± 8.69
   IV 5 127.00 ± 1.41
Curative resectionb) <0.001 0.016
   Yes 24 109.13 ± 13.17
   No 6 124.37 ± 5.00
CEAc) 0.641 0.979
   ≤5 21 110.52 ± 13.44
   >5 6 113.50 ± 14.26
cfDNA, circulating free DNA; SD, standard deviation; CEA, carcinoembryonic antigen.
a)Generalized linear-regression model; variables of age, sex, and smoking were adjusted. b)Curative resection means R0 resection (no 
residual tumor), R1 (microscopic residual tumor), nd R2 resections (macroscopic residual tumor) are included in the noncurative 
resection groups. c)Total number of cases with preoperative CEA level checked were 27 cases.
Fig. 2. Receiver operating characteristic (ROC) curve of 
circulating free DNA between cancer patients and healthy 
controls. AUC, area under the curve.
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= 0.037). N stage is not associated with cfDNA. CfDNA in high-
TNM stage is higher than in low-TNM stage and is significant 
after adjustment for age, sex and smoking (P = 0.048). Variable 
of curability is significantly associated with cfDNA when 
unadjusted and adjusted, respectively (P < 0.001 and P = 0.016).
CfDNA is not associated with the tumor marker of CEA. All 
CA 19-9 in patients with gastric cancer were within normal 
ranges, and correlation between CA 19-9 and cfDNA is not 
significant (data are not shown). CEA and CA 19-9 are not 
associated with variables that represent the tumor burden such 
as cancer progression (EGC vs. AGC) and TNM stage (data are 
not shown). 
Compared to the mean levels of cfDNA in the preoperation 
group, the mean levels of cfDNA in the 24-hour-after-surgery 
group decreased significantly (112.17 ± 13.42 ng/mL vs. 77.93 ± 
5.94 ng/mL, P < 0.001) (Fig. 3).
DISCUSSION
There is an increased incidence of stomach cancer cases 
in Korea, indicating a need for an applicable biomarker for 
better screening and management. According to the Korean 
National Cancer Incidence Database, in 2010, 202,053 incidents 
of cancer cases and 72,046 deaths were identified in Korea. 
The most prevalent cancer was thyroid cancer (36,021 cases), 
and the next most prevalent cancer was stomach cancer (total 
30,092 cases: 2,017 males and 9,913 females). A total of 10,032 
patients died due to stomach cancer in 2010. The crude rate of 
cancer incidence was 259.9 per 100,000 in the general Korean 
population. The age-standardized incidence rate of gastric 
cancer per 100,000 populations was 41.8 (males 62.3, females 
24.9) in 2010 in Korea [14]. Also, Park et al. [15] reported that 
the incidence of second primary cancer (SPC) in male cancer 
survivors was 603.2 per 100,000 person-years, which was about 
2.3 times compared to the incidence of the general population.
Thus, the incidence of gastric cancer and the SPC risk of 
cancer survivors in South Korea are much higher than in 
other countries. Although health screening for early diagnosis 
and follow-up tools are high, the use of conventional tumor 
markers (CEA, CA 19-9, CA 72-4, etc.) has many limits due to 
low sensitivity and specificity. So, more sensitive and specific 
biomarkers should be used for stomach cancer detection in 
Korea.
In this pilot study, we evaluated the efficacy of cfDNA as 
a biomarker that discriminates cancer patients from healthy 
subjects. The main finding of this study was that the plasma 
level of cfDNA is able to differentiate tumor burden such as 
tumor size, depth of invasion, and tumor stage. In our study, 
some demographic characteristics of patients with gastric 
cancer, such as age, sex and smoking, are associated with 
plasma-mean cfDNA levels. An unexpected result is that the 
levels of cfDNA are higher in the nonsmoking groups than the 
smoking groups. However these variables are not different in 
the healthy control group (Table 1). This may be due to the fact 
that the cancer type in the particular variables such as aged, 
female, non-smoker is more aggressive than others in this small 
sampled study. 
Many studies have demonstrated that cfDNA levels have 
discriminatory power to differentiate cancer patients from 
healthy controls. As a diagnostic tool, sensitivity and specificity 
of cfDNA between cancer patients and healthy controls varies. 
Kamat et al. [16] demonstrated that a cutoff value of 4,500 GE/
mL of cfDNA yielded a sensitivity of 87% and a specificity 
of 87% among 164 women with invasive epithelial ovarian 
carcinoma, 49 with benign ovarian neoplasms, and 75 age-
matched controls. Another study showed cfDNA from plasma in 
metastatic colorectal cancer patients yields a specificity of 97% 
and a sensitivity of 31% [17]. Our study showed a much higher 
diagnostic value both in sensitivity and specificity compared to 
previous studies.
Furthermore, cfDNA can be a possible biomarker to 
differentiate the invasiveness of tumors. Increased serum 
cfDNA levels in relationship to tumor size are predictive of 
distant metastasis of esophageal squamous cell carcinoma 
[18]. Agostini et al. [19] demonstrated that cfDNA in breast 
cancer patients is associated with lymph-node involvement, 
but not with tumor stage and vascular invasion. The level 
of cfDNA was associated with malignant tumor size, lymph-
node involvement, stage, and grade, as well as Her2/neu 
and Topoisomerase IIα expression, in breast cancer patients 
[20]. This study also demonstrated that the levels of cfDNA 
in plasma are proportionally associated with parameters 
representing the invasiveness of gastric tumors such as clinical 
cancer type (EGC vs. AGC), tumor size, and tumor stage, but not 
with histological differentiation and lymph-node involvement. 
In contrast to the cfDNA in this study, CEA and CA 19-9 are not 
associated with tumor stage and histological tumor type (data 
Fig. 3. Comparison of mean circulating free DNA levels 
between pre- and postoperation in patients with gastric 
cancer.
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